Previous 10 | Next 10 |
Summary Cryoport has significantly underperformed the broader market over the past several months, largely due to poor earnings and cash flows. The company has excess cash on its books, but this doesn't make it a great prospect when you consider its continued profitability issues. A...
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibr...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2022 and provided...
Summary A reasonable period of top-line growth across the core portfolio last quarter, coupled with strong guidance for FY22. Despite this, operating losses continue to widen, and NOPAT is thin even when capitalizing on R&D. A combination of technicals, market positioning, and q...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthc...
Recognizes Exemplary Board Practices Related to DE&I AtriCure Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that i...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual Piper Sandler Healthcare Confe...
AtriCure, Inc. (ATRC) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Particip...
AtriCure press release ( NASDAQ: ATRC ): Q3 GAAP EPS of -$0.27 misses by $0.02 . Revenue of $83.2M (+18.1% Y/Y) beats by $1.88M . 2022 Financial Guidance Full year 2022 revenue is projected to be approximately $328 million to $333 million vs $328.61M consen...
News, Short Squeeze, Breakout and More Instantly...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...